Tag: tyrosine kinase inhibitors (TKIs)

23-URL-4036562 CQD 650×450 B

Targeted Neoadjuvant Therapy For High-Complexity Cases of Renal Masses in a Solitary Kidney

Management of high-risk RMSK in the pre-and current eras of neoadjuvant therapy

650×450-partial-nephrectomy
May 16, 2022/Cancer

For Cancer in a Solitary Kidney, Preserving Function Is Almost Always Possible

Analysis is one of the largest-ever series of RMSK outcomes, first to include all RMSK patients

PrimaryPulmonaryCarcinoid
June 29, 2021/Cancer/Tumor Oncology

Achieving Cost-Effectiveness with Adjuvant Osimertinib for NSCLC

Model identifies target OS at which economic benefits of treatment outpace placebo

20-PSX-1944053-Cutaneous-adverseEffects-TKIs-hero-CQD-650×450
August 17, 2020/Cancer

Cutaneous Adverse Effects of Small-Molecule Tyrosine Kinase Inhibitors

Side effects and management strategies

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

BackPage 1 of 1Next

Advertisement

Ad